The University of Texas System

The Dow Chemical Company

Robert Talbert

Keith P Johnston

Robert O Williams, Iii

True L Rogers

Jason T McConville

Jay I Peters

Alan B Watts

Prapasri Sinswat

Christopher John Tucker

Timothy J Young

Brian D Scherzer

James E Hitt

David A Hayes

Ian B Gillespie

Paula C Garcia

Nicholas S Beck

David S Burgess

Robert O Iii Williams

Prapasri Sinwat

The present invention includes compositions and methods for making and using a rapid dissolving, high potency, substantially amorphous nanostructured aggregate for pulmonary delivery of tacrolimus and a stabilizer matrix comprising, optionally, a polymeric or non-polymeric surfactant, a polymeric or non-polymeric saccharide or both, wherein the aggregate comprises a surface area greater than 5 m/g as measured by BET analysis and exhibiting supersaturation for at least 0.5 hours when 11-15-times the aqueous crystalline solubility of tacrolimus is added to simulated lung fluid.

Methods for making compositions for pulmonary administration

Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery

Inhalable compositions are described. The inhalable compositions comprise one or more respirable aggregates, the respirable aggregates comprising one or more poorly water soluble active agents, wherein at least one of the active agents reaches a maximum lung concentration (C) of at least about 0.25 &#x3bc;g/gram of lung tissue and remains at such concentration for a period of at least one hour after being delivered to the lung. Methods for making such compositions and methods for using such compositions are also disclosed.

Enhanced delivery of drug compositions to treat life threatening infections

Growing community of inventors

San Antonio, TX, United States of America

Robert Talbert